The Journal of rheumatology · 1996
The use of methotrexate in polymyalgia rheumatica.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Feinberg H L, Sherman J D, Schrepferman C G, Dietzen C J, Feinberg G D
Аннотация
OBJECTIVE: To examine the efficacy and steroid sparing potential of methotrexate (MTX) in the treatment of polymyalgia rheumatica (PMR) without giant cell arteritis.
METHODS: 43 patients with PMR were treated with MTX 7.5 mg/wk for 3 months. This dose was raised to 10 and finally 12.5 mg/wk MTX if the desired response was not obtained.
RESULTS: No patient benefitted clinically or statistically from treatment with MTX.
CONCLUSION: MTX is of no benefit in the treatment of PMR.
METHODS: 43 patients with PMR were treated with MTX 7.5 mg/wk for 3 months. This dose was raised to 10 and finally 12.5 mg/wk MTX if the desired response was not obtained.
RESULTS: No patient benefitted clinically or statistically from treatment with MTX.
CONCLUSION: MTX is of no benefit in the treatment of PMR.